Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From CureVac NV

Novartis Bounces Back From COVID-19 And Cosentyx Keeps Climbing

Sales at the Swiss major have returned to around 80%-90% of their pre-pandemic levels, according to CFO Harry Kirsch after unveiling a healthy set of second-quarter financials.

Sales & Earnings Business Strategies

Shifting Goalposts For Vaccine Cos As Lambda Variant Rears Head

Studies point to Johnson & Johnson, Pfizer and Bharat Biotech’s vaccines neutralizing the Delta variant of SARS-CoV-2, even if efficacy is lower compared to the original strain. This follows positive news from other vaccine companies but will the Lambda variant cause a setback?

Vaccines Research & Development

Can Moderna Repeat COVID-19 Success In Influenza Market?

The company could have a significant competitive position thanks to the ability to rapidly develop and combine vaccines using mRNA technology.

Infectious Diseases Vaccines

CureVac Still Hopes Variants Could Win Favor For COVID-19 Vaccine

Patients 18-60 had a protection rate of 53%, but there were too few cases among those older than 60 – a crucial subgroup – in HERALD to draw conclusions about the vaccine’s efficacy among older people.

Coronavirus COVID-19 Vaccines
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Other Names / Subsidiaries
    • CureVac GmbH
    • CureVac BV
UsernamePublicRestriction

Register